Surgery – Internal organ support or sling
Reexamination Certificate
2002-02-25
2003-04-08
Getzow, Scott M. (Department: 3762)
Surgery
Internal organ support or sling
Reexamination Certificate
active
06544168
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention is generally directed to a device and method for reinforcement of the cardiac wall. The invention is particularly suited for the treatment of cardiac disease which result in a trial or ventricular dilation. The invention provides reinforcement of the cardiac wall during diastolic chamber filling to prevent or reduce cardiac dilation in patients known to have experienced such dilation or who have a predisposition for such dilation occurring in the future. The cardiac reinforcement structure is typically applied to the epicardial surface of the heart.
Cardiac dilation occurs with different forms of cardiac disease, including heart failure. In some cases, such as post-myocardial infarction, the dilation may be localized to only a portion of the heart. In other cases, such as hypertrophic cardiomyopathy, there is typically increased resistance to filling of the left ventricle with concomitant dilation of the left atria. In dilated cardiomyopathy, the dilation is typically of the left ventricle with resultant failure of the heart as a pump. In advanced cases, dilated cardiomyopathy involves the majority of the heart.
With each type of cardiac dilation, there are associated problems ranging from arrhythmias which arise due to the stretch of myocardial cells, to leakage of the cardiac valves due to enlargement of the valvular annulus. Devices to prevent or reduce dilation and thereby reduce the consequences of dilation have not been described. Patches made from low porosity materials, for example Dacron™, have been used to repair cardiac ruptres and septal defects, but the use of patches to support the cardiac wall where no penetrating lesion is present has not been described.
Drugs are sometimes employed to assist in treating problems associated with cardiac dilation. For example, digoxin increases the contractility of the cardiac muscle and thereby causes enhanced emptying of the dilated cardiac chambers. On the other hand, some drugs, for example, beta-blocking drugs, decrease the contractility of the heart and thus increase the likelihood of dilation. Other drugs including angiotensin-converting enzyme inhibitors such as enalopril help to reduce the tendency of the heart to dilate under the increased diastolic pressure experienced when the contractility of the heart muscle decreases. Many of these drugs, however, have side effects which make them undesirable for long-term use.
Accordingly, there is a need for a device that can reduce or prevent cardiac dilation and reduce the problems associated with such dilation.
SUMMARY OF THE INVENTION
The present invention is directed to a device and method for reinforcement of the cardiac wall. According to the invention, a cardiac reinforcement device includes a biomedical material which can be applied to the epicardial surface of the heart and which expands to a predetermined size that is selected to constrain cardiac expansion beyond a predetermined limit. A biomedical material suitable for a cardiac reinforcement device can be an elastic or nonelastic mesh or non-mesh material.
In one embodiment, a cardiac reinforcement device is a biomedical material in the form of a patch. The size of the patch is selected to locally constrain cardiac expansion.
In another embodiment, a cardiac reinforcement device is a biomedical material shaped as a jacket with a predetermined size selected for the jacket to surround the epicardial surface of the heart and circumferentially constrain cardiac expansion. In one embodiment, a cardiac reinforcement jacket may be applied to the epicardial surface via a minimally invasive procedure such as thorascopy.
A cardiac reinforcement jacket can include a securing arrangement for securing the jacket to the epicardial surface of the heart. The cardiac reinforcement jacket can also include a mechanism for selectively adjusting the predetermined size of the jacket around the epicardial surface of the heart. The adjustment mechanism can include a slot having opposing lateral edges which when pulled together decrease the volumetric size of the jacket. In an alternative embodiment, a selective size adjustment mechanism can include an inflatable member mounted between the jacket and the epicardial surface of the heart. Inflation of the inflatable member provides for reduction in the volumetric size of the jacket.
A cardiac reinforcement device of the invention can be used to treat cardiomyopathy or to reduce the diastolic volume of the heart.
REFERENCES:
patent: 3983863 (1976-10-01), Janke et al.
patent: 4048990 (1977-09-01), Goetz
patent: 4403604 (1983-09-01), Wilkinson et al.
patent: 4428375 (1984-01-01), Ellman
patent: 4630597 (1986-12-01), Kantrowitz et al.
patent: 4690134 (1987-09-01), Snyders
patent: 4821723 (1989-04-01), Baker, Jr. et al.
patent: 4834707 (1989-05-01), Evans
patent: 4878890 (1989-11-01), Bilweis
patent: 4936857 (1990-06-01), Kulik
patent: 4957477 (1990-09-01), Lundback
patent: 4973300 (1990-11-01), Wright
patent: 4976730 (1990-12-01), Kwan-Gett
patent: 5057117 (1991-10-01), Atweh
patent: 5087243 (1992-02-01), Avitall
patent: 5131905 (1992-07-01), Grooters
patent: 5150706 (1992-09-01), Cox et al.
patent: 5186711 (1993-02-01), Epstein
patent: 5192314 (1993-03-01), Daskalakis
patent: 5256132 (1993-10-01), Snyders
patent: 5290217 (1994-03-01), Campos
patent: 5356432 (1994-10-01), Rutkow et al.
patent: 5383840 (1995-01-01), Heilman et al.
patent: 5385156 (1995-01-01), Oliva
patent: 5429584 (1995-07-01), Chiu
patent: 5507779 (1996-04-01), Altman
patent: 5524633 (1996-06-01), Heaven et al.
patent: 5603337 (1997-02-01), Jarvik
patent: 5647380 (1997-07-01), Campbell et al.
patent: 5702343 (1997-12-01), Alferness
patent: 5713954 (1998-02-01), Rosenberg et al.
patent: 5800528 (1998-09-01), Lederman et al.
patent: 3831540 (1989-04-01), None
patent: 3831540 (1993-06-01), None
patent: 295 17 393 (1996-03-01), None
patent: 0 280 564 (1988-08-01), None
patent: 2209678 (1989-05-01), None
patent: 60203250 (1985-10-01), None
patent: 01-145066 (1989-06-01), None
patent: 1009457 (1983-04-01), None
patent: WO 98/29041 (1998-07-01), None
patent: WO 98/58598 (1998-12-01), None
“Abstracts From the 68th Scientific Sessions, Anaheim Convention Center, Anaheim, California, Nov. 13-16, 1995”,American Heart Association Supplement to Circulation, vol. 92, No. 8, Abstracts 1810-1813 (Oct. 15, 1995).
Capomolla et al., “Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: Hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function”,American Heart Journal. vol. 134, No. 6, pp. 1089-1098 (Dec. 1997).
Capouya et al., “Girdling Effect of Nonstimulated Cardiomyoplasty on Left Ventricular Function,”Ann. Thorac. Surg56:867-871 (1993).
Coletta et al., “Prognostic value of left ventricular volume response during dobutamine stress echocardiography”,European Heart Journal, vol. 18, pp. 1599-1605 (Oct. 1997).
Jay N. Cohn, “The Management of Chronic Heart Failure”,The New Eng. J. of Med., 335(7): 490-498 (Aug. 15, 1996).
David A. Kass et al., “Reverse Remodeling From Cardiomyoplasty in Human Heart Failure, External Constraint Versus Active Assist”,Circulation 91(9): 2314-2318 (May 1, 1995).
Howard R. Levin et al., “Reversal of Chronic Ventricular Dilation in Patients With End-Stage Cardiomyopathy by Prolonged Mechanical Unloading”,Circulation 91(11): 2717-2720 (Jun. 1, 1995).
Oh et al., “The Effects of Prosthetic Cardiac Binding and Adynamic Cardiomyoplasty in a Model of Dilated Cardiomyopathy,”The Journal of Thoracic and Cardiovascular Surgery, 116(1):148-153 (Jul. 1998).
Paling, “Two-Bar Fabrics (Part-Set Threading)”,Warp Knitting Technology, Columbine Press (Publishers) Ltd., Buxton, Great Britain, p. 111 (1970).
Revista Española de Cardiologia, vol. 51, No. 7, Jul. 1998 (Abstract in English).
Abstract: Mikhail Vaynblat et al., “Cardiac Binding in Experimental Heart Failure,”Abstract in Supplement to Circulation92(8):1810 (Oct. 15, 1995).
Acorn Cardiovascular Inc.
Getzow Scott M.
Merchant & Gould P.C.
LandOfFree
Cardiac reinforcement device does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiac reinforcement device, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiac reinforcement device will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3010840